Original Articles
Copyright ©The Author(s) 1998. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 15, 1998; 4(3): 225-227
Published online Jun 15, 1998. doi: 10.3748/wjg.v4.i3.225
A clinical evaluation of serum concentrations of intercellular adhesion molecule-1 in patients with gastric cancer
Yong-Zhong Liu, Bin Chen, Xi-Dian She
Yong-Zhong Liu, Bin Chen, Xi-Dian She, Institute of Clinical Medical Sciences, Affiliated Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui Province, China
Yong-Zhong Liu, male, born in 1968 in Anhui Province, graduated from Shandong Academy of Medical Sciences as a postgraduate in 1996, having 4 papers published.
Author contributions: All authors contributed equally to the work.
Correspondence to: Yong-Zhong Liu, Institute of Clinical Medical Sciences, Affiliated Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui Province, China
Telephone: +86-553-5855956-2328
Received: November 10, 1997
Revised: March 4, 1998
Accepted: May 20, 1998
Published online: June 15, 1998

AIM: To investigate the correlation between the serum soluble intercellular adhesion molecule-1 (sICAM-1) and the clinicopathologic features and to evaluate the possible prognostic significance of sICAM-1 concentration in gastric cancer.

METHODS: Thirty-four patients with gastric cancer were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and store at -30 °C until assay. The control group consisted of 20 healthy volunteers. Serum concentrations of ICAM-1 were measured with the quantitative sandwich enzyme immunoassay technic. Differences between the two groups were analyzed by Student’s t test. x- + 2s of normal control sICAM-1 was taken as upper limit to calculate the positive rates.

RESULTS: The mean value of serum ICAM-1 in patients with gastric cancer was 367.7 μg/L ± 104.7 μg/L and that of control group was 236.9 μg/L ± 74.3 μg/L, and the difference was significant (P < 0.001). The patients with tumor size of ≥ 5 cm had significantly higher serum concentrations of sICAM-1 than those with smaller ones (406.7 μg/L ± 90.2 μg/L vs 319.9 μg/L ± 105.3 μg/L, P < 0.01). Compared with stages I-II gastric cancer patients, patients with more advanced clinical stage (III-IV) had higher levels of sICAM-1 (397.1 μg/L ± 102.4 μg/L vs 306.0 μg/L ± 82.3 μg/L, P < 0.05). Difference was significant statistically in sICAM-1 levels between patients with positive lymph node status and those without lymph node involvement (403.6 μg/L ± 99.7 μg/L vs 302.7 μg/L ± 81.4 μg/L, P < 0.01). No relation was observed between the level of sICAM-1 and grade of histological differentiation in the patients with gastric cancer.

CONCLUSION: Serum sICAM-1 concentration may be a valuable parameter for predicting the prognosis and degree of the gastric cancer.

Keywords: stomach neoplasms/immunology, intercellular adhesion molecule-1/blood, lymphatic metastasis, intercellular adhesion molecule-1/analysis, enzyme-linked immunosorbent assay